Future Financial Wealth Managment LLC Makes New Investment in Gilead Sciences, Inc. (NASDAQ:GILD)

Future Financial Wealth Managment LLC bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 2,200 shares of the biopharmaceutical company’s stock, valued at approximately $161,000.

A number of other large investors have also recently made changes to their positions in GILD. Etesian Wealth Advisors Inc. grew its position in Gilead Sciences by 0.7% during the 4th quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock worth $1,486,000 after purchasing an additional 128 shares during the period. Financial Counselors Inc. grew its holdings in Gilead Sciences by 1.5% during the fourth quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock worth $718,000 after acquiring an additional 128 shares during the period. Revolve Wealth Partners LLC raised its position in Gilead Sciences by 3.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock valued at $292,000 after acquiring an additional 130 shares in the last quarter. Steph & Co. lifted its holdings in Gilead Sciences by 1.9% in the fourth quarter. Steph & Co. now owns 7,548 shares of the biopharmaceutical company’s stock valued at $611,000 after acquiring an additional 142 shares during the period. Finally, First Affirmative Financial Network boosted its position in Gilead Sciences by 3.5% in the 1st quarter. First Affirmative Financial Network now owns 4,342 shares of the biopharmaceutical company’s stock worth $318,000 after purchasing an additional 147 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the transaction, the insider now directly owns 96,304 shares of the company’s stock, valued at $7,026,339.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Stock Down 0.7 %

GILD stock opened at $68.83 on Friday. The company has a current ratio of 1.08, a quick ratio of 0.94 and a debt-to-equity ratio of 1.31. The firm has a 50-day moving average of $65.89 and a two-hundred day moving average of $72.75. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $87.86. The company has a market cap of $85.75 billion, a price-to-earnings ratio of 191.19, a PEG ratio of 2.95 and a beta of 0.20.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, beating the consensus estimate of ($1.49) by $0.17. The firm had revenue of $6.69 billion during the quarter, compared to analysts’ expectations of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.37 earnings per share. As a group, analysts forecast that Gilead Sciences, Inc. will post 3.75 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Stockholders of record on Friday, June 14th were given a dividend of $0.77 per share. The ex-dividend date was Friday, June 14th. This represents a $3.08 annualized dividend and a dividend yield of 4.47%. Gilead Sciences’s payout ratio is 855.56%.

Analysts Set New Price Targets

GILD has been the subject of several analyst reports. Maxim Group decreased their target price on shares of Gilead Sciences from $90.00 to $85.00 and set a “buy” rating for the company in a research note on Wednesday, May 1st. UBS Group decreased their price objective on shares of Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. Needham & Company LLC restated a “hold” rating on shares of Gilead Sciences in a research report on Friday, April 26th. HSBC upgraded Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 price target for the company in a research note on Wednesday, April 24th. Finally, Morgan Stanley dropped their price objective on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating on the stock in a report on Friday, April 26th. Twelve analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $83.47.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.